Abstract
Introduction The presentation and publication of the Jupiter trial in November 2008 was greeted by acclaim and skepticism within the cardiovascular community [1,2]. Why was there such a “bimodal” response to this pivotal clinical trial? Jupiter represents a classic example of the dilemma now facing clinical decision making in the contemporary cardiovascular medicine. Can we provide incremental value using new therapeutic strategies and what price are we willing to pay for such progress? Depending on your point of view, the Jupiter trial was either a resounding success or an overzealous effort to extend statin treatment to an unreasonably broad population. Let us examine the facts.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
